AllianceBernstein
KALV

AllianceBernstein’s KalVista Pharmaceuticals KALV Stock Holding History

AllianceBernstein’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$542K Sell
33,580
-6,440
-16% -$104K ﹤0.01% 2598
2025
Q4 		$646K Hold
40,020
– – ﹤0.01% 2532
2025
Q3 		$487K Hold
40,020
– – ﹤0.01% 2694
2025
Q2 		$452K Hold
40,020
– – ﹤0.01% 2702
2025
Q1 		$462K Hold
40,020
– – ﹤0.01% 2588
2024
Q4 		$339K Hold
40,020
– – ﹤0.01% 2810
2024
Q3 		$463K Sell
40,020
-2,430
-6% -$30.6K ﹤0.01% 2692
2024
Q2 		$500K Buy
42,450
+12,440
+41% +$145K ﹤0.01% 2667
2024
Q1 		$356K Hold
30,010
– – ﹤0.01% 2740
2023
Q4 		$368K Sell
30,010
-2,400
-7% -$21.8K ﹤0.01% 2758
2023
Q3 		$312K Hold
32,410
– – ﹤0.01% 2790
2023
Q2 		$292K Buy
32,410
+6,710
+26% +$61.9K ﹤0.01% 2872
2023
Q1 		$202K Hold
25,700
– – ﹤0.01% 2903
2022
Q4 		$174K Buy
25,700
+8,636
+51% +$46.3K ﹤0.01% 3034
2022
Q3 		$248K Buy
17,064
+1,964
+13% +$27.5K ﹤0.01% 2945
2022
Q2 		$149K Buy
15,100
+4,700
+45% +$51.8K ﹤0.01% 3074
2022
Q1 		$153K Sell
10,400
-1,800
-15% -$25.9K ﹤0.01% 3050
2021
Q4 		$161K Hold
12,200
– – ﹤0.01% 3126
2021
Q3 		$213K Hold
12,200
– – ﹤0.01% 3069
2021
Q2 		$292K Buy
+12,200
New +$319K ﹤0.01% 3017
2021
Q1 		– Sell
-18,800
Closed -$357K – 3267
2020
Q4 		$357K Sell
18,800
-900
-5% -$15.4K ﹤0.01% 2768
2020
Q3 		$248K Hold
19,700
– – ﹤0.01% 2891
2020
Q2 		$238K Buy
19,700
+7,400
+60% +$78.7K ﹤0.01% 2958
2020
Q1 		$94K Buy
12,300
+2,200
+22% +$29.7K ﹤0.01% 2971
2019
Q4 		$180K Hold
10,100
– – ﹤0.01% 2944
2019
Q3 		$117K Buy
+10,100
New +$163K ﹤0.01% 3051

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AllianceBernstein's KALV Position: Q1 2026 in Review

AllianceBernstein reduced its KalVista Pharmaceuticals (KALV) stake by 16% in Q1 2026, selling an estimated $104K and leaving 33,580 shares worth $542K. The position accounts for ﹤0.01% of the portfolio, ranked #2598.

AllianceBernstein first reported a position in KALV in Q3 2019 and has held it in 26 quarters since. The position peaked at $646K in Q4 2025. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

  • AllianceBernstein held 33,580 shares of KalVista Pharmaceuticals worth $542K as of Q1 2026.
  • AllianceBernstein sold 6,440 KalVista Pharmaceuticals shares in Q1 2026, an estimated $104K.
  • KalVista Pharmaceuticals made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #2598 holding.
  • AllianceBernstein first reported a position in KalVista Pharmaceuticals in Q3 2019 and has held it in 26 quarters since.
  • AllianceBernstein's KalVista Pharmaceuticals position peaked at $646K in Q4 2025.
  • 183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.